85
Participants
Start Date
December 14, 2012
Primary Completion Date
April 26, 2016
Study Completion Date
May 20, 2016
Docetaxel, Reolysin and Prednisone
Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
Docetaxel and Prednisone
Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BCCA - Abbotsford Centre, Abbotsford
BCCA - Cancer Centre for the Southern Interior, Kelowna
BCCA - Fraser Valley Cancer Centre, Surrey
BCCA - Vancouver Cancer Centre, Vancouver
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
London Regional Cancer Program, London
Ottawa Hospital Research Institute, Ottawa
Allan Blair Cancer Centre, Regina
Collaborators (1)
Oncolytics Biotech
INDUSTRY
Canadian Cancer Trials Group
NETWORK